GHB and its related compounds have been known for years in forensic toxicology because of their illicit use in drug-facilitated sexual assault, and to a lesser extent, as party drugs. A sensitive and specific method for the identification and quantification of gamma-hydroxybutyric acid (GHB) in saliva has been developed using gas chromatography-mass spectrometry with selective ion monitoring mode. One microliter of synthetic saliva was spiked with 1.0 pt of GHB-d6 as the internal standard and 1.0 pL of 1,7-heptanediol as a surrogate spike to all samples. After a silylderivatization, the sample was injected at a split ratio of 10:1. The following ions were monitoring: 233 and 234 for GHB; 239, 240, and 241 for GHB-d6; and 55, 73, and 97 for 1,7-heptanediol. The limit of quantitation was determined to be 0.5 mg/L with a linear dynamic range of 0.5-50.0 mg/L. Quality control samples (5.0, 20.0, and 30.0 rag/L) were prepared for the evaluation of precision. Analytical precision measured by coefficients of variation ranged from 2.1% to 12.50% in both intraday and dayto-day experiments. Surrogate recovery from saliva samples fell in the range of 94.6% to 100% with an average of 98.37% and a corresponding percent relative standard deviation of 1.2%.
Introduction
y-Hydroxybutyric acid (GHB) and its precursors y-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) have become common drugs of abuse in the U.S. since the beginning of the 1980s (1) . Currently, street formulations of GHB are Schedule I substances. Overdosing of GHB easily occurs due to the imprecise GHB concentrations in samples obtained on the street (2) . After oral ingestion, GHB is eliminated following zeroorder kinetics; therefore, its elimination rate is dose-dependent. Because of GHB's rapid elimination, the collection of biological specimens for toxicological testing must be prompt to avoid misunderstanding between exogenous and endogenous concentration. In 2002, Elian (3) suggested, as the result of the surveys, the cut-off levels of 10.0 and 5.0 mg/L in urine and blood, respectively.
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The use of alternative specimens to blood or urine for establishing exposure to drugs has become of interest in clinical and forensic toxicology. Unconventional matrices include hair, sweat, and oral fluid. In particular, oral fluid showed the right characteristics for the purpose of our research: a rapid and sensitive screening for the detection of GHB. Collecting saliva can be done by non-specialists, is quite fast (4), and is generally considered to be less invasive than collecting either blood or urine (5) . Furthermore, there is a correlation between an oral fluid drug concentration and blood/plasma concentration. However, an extensive literature review failed to uncover any studies reporting a partition coefficient for GHB in plasma and saliva.
As Drummer (6) reported in his review, oral fluid is not used with the intent to replace the use of the traditional specimens; however, if evidence of recent use (acute intoxication) of drugs is probed, then both saliva and blood are preferred specimens (urine when evidence of prior exposure to drugs of abuse is investigated and hair when a longer time frame of exposure to drugs is investigated). The use of saliva to detect drugs has a wide range of application: possible drug-affected drivers, testing on workplace or persons in prisons, and crimes committed under the influence of a drug.
Drug monitoring in saliva is not a new procedure; many studies have been led for at least 30 years (7) aiming principally at methamphetamine and other amphetamines (8-10), cannabis (11) (12) (13) (14) (15) , cocaine (16) (17) (18) (19) , opiates (20) (21) (22) (23) (24) (25) (26) (27) , and benzodiazepines (28, 29) .
Other compounds of forensic interest measured in oral fluid were hydromorphone (30) , phencyclidine (31), pholcodine (32) , sildenafil (33) , carbamazepine (34) , topiramate (35) , methadone (36) , digoxin (37) , disopyramide (38) , docetaxel, and paclitaxel (39) . In the last few decades, the consumption of GHB as a recreational substance has required the development of new methods of analysis and the utilization of alternative matrices. Concerning this, GHB has been investigated in hair (40) (41) (42) (43) (44) (45) , vitreous humor, urine, bile, brain, liver, kidney, and cerebrospinal fluid (46) (47) (48) (49) in both antemortem and postmortem samples. To date, there are only two articles in literature concerning GHB analysis in saliva (50, 51) .
The purpose of the present work was to introduce the potential use of saliva as an alternative biological matrix as a tool in GHB screening analysis and to establish gas chromatography-mass spectrometry (GC-MS) as a sensitive analytical technique for GHB detection in saliva.
Materials and Methods

Specimen
OraFlx Negative Oral Fluid was purchased from Cerilliant (Round Rock, TX). GHB synthetic saliva standards were prepared and used as calibrators and quality control sample for the validation process.
Saliva samples were obtained from healthy volunteers of our lab and collected with the Sarstedt Salivette | devices (N~mbrecht, Germany) according to the manufacturer's instructions. As per the applicable Institutional Review Board, no personal or health data were requested, collected, or retained. Briefly, after chewing of the cotton wool swab for I rain, the device was placed in the supplied tube and centrifuged 10 min at 3500 rpm. After centrifuging, the volume of saliva recovered was approximately 1.0 mL for each tube. One microliter of each sample was immediately analyzed. The remaining amount of saliva sample was sealed and stored at -20~
Chemicals and reagents
GHB sodium salt and 1,7-heptanediol were from Sigma (St. Louis, MO). GHB-d6 (1000.0 mg/L methanol solution), the internal standard, was purchased from Cerilliant. 
GHB sample preparation
Prior to analysis, pipettes were checked and calibrated according to standard laboratory protocols. The pipette (0.5-5.0 IJL capacity) was checked at two volume settings (1.0 and 5.0 IJL) using six replicate measurements. Accuracy at 1.0 pL was -3.35%, which was within the stated tolerance of + 5.0%. The relative standard deviation (RSD) at 1.0 IJL was 1.3%.
One microliter of synthetic saliva (pH 7.5; composition is proprietary and thus unknown) was spiked with 1.0 pL of GHB-d6 (internal standard) and 1.0 pL of 1,7-heptanediol (as a surrogate spike). A surrogate is a compound that is similar to the analyte of interest. It is spiked into all samples and blanks. The purpose of the surrogate in the present case is to assist in identifying and tracking any analyte loss attributed to the sample preparation procedure. For example, potential transfer or dilution errors can be identified through evaluation of the percent recovery of the surrogate compound. The advantage of a surrogate over traditional accuracy and precision determinations is that the surrogate is analyzed in every sample. This approach, widely used in environmental chemistry, has been shown to be valuable when analytes are embedded in complex matrices. The surrogate provides an additional degree of control over matrix effects, given that recovery of the surrogate compound is anticipated to track that of the target compound; here, GHB. The sample was derivatized by adding 97.0 pL BSTFA+1% TMCS, then incubated for 30 min at 50~ GC-MS procedure A 1.0-pL aliquot of the derivatized sample was injected into the column of an Agilent 6890 series GC. The flowrate carrier gas (helium, purity grade N55) was 1.0 mL/min through the Rtx-5MS Restek (Bellefonte, PA) capillary column (5% diphenyl 95% dimethyl polysiloxane, 30 m x 0.25-mm i.d., 0.5-pro film thickness). The injector temperature was 195~ and split injection was employed with a ratio of 10:1. The column oven temperature was programmed to rise from an initial temperature of 40~ maintained for 2 min, increased to 300~ at a rate of 20~ and held at 300~ for I min. An Agilent 5973 mass selective detector in selected ion monitoring (SIM) mode coupled to the GC was used for quantitative analysis. The electron impact of 70 eV was used for the ionization of the compounds. The following ions were monitored: m/z 23___33 and 234 for GHB and m/z 239 and 240 for GHB-d 6 at dwell 220 ms and m/z 55, 7__33, and 97 for 1,7-heptanediol at dwell 400 ms (quantification ions are underlined).
Method validation
A standard calibration curve (n = 6) was obtained by preparing standards containing 0.5, 1.0, 5.0, 10.0, 25.0, and 50.0 mg/L of spiked GHB. The precision for GHB was determined using quality control samples of saliva spiked at 5.0, 20.0, and 30.0 mg/L with GHB. The quality control samples were analyzed in five replicates on three different days, respectively. The limit of quantification was evaluated by diluting GHB synthetic saliva standard with saliva until a response equivalent to the GHB concentration in saliva matrix gave a signal-to-noise ratio equivalent to 10. The detection limit was evaluated by diluting saliva until a response equivalent to three times the background noise was observed.
Results and Discussion
Under the chromatographic conditions used, no interfering peaks were observed. There were no blank effects. Figures 1  and 2 show the chromatogram of blank saliva and the same sample spiked with GHB, GHB-d6 (IS), and 1,7-heptanediol (surrogate spike), respectively. Figure 3 is the typical SIM chromatogram of GHB di-TMS, GHB-d6 di-TMS, and 1,7-heptanediol di-TMS. Selected ions and retention times for GHB, GHB-d6, and 1,7-heptanediol are reported in Table I . Because the retention times for GHB and its deuterated analogue were so close, unique ions for GHB and GHB-d6 were selected. This facilitated automatic identification by the software and afforded accurate quantitation.
The calibration curve corresponds to the linear regression between the peak-area ratio of GHB to IS and the final concentration of the drug in spiked saliva. Standard curves for GHB in saliva were linear in the range 0.5 to 50.0 mg/L. The correlation for the standard curves was described by the following equation: y = 45.627x + 170.8 with an R ~ value of 0.998 for GHB.
Tables II and II! represent the accuracy and precision of the analytical method for the quantification of GHB. The intraday variability was determined by analyzing five replicate controls prepared in synthetic saliva spiked at 5.0, 20.0, and 30.0 mg/L on a single day. The day-to-day variability was determined on three different days using the same concentrations. The limit of quantification was the first point of the calibration curve, which is 0.5 mg/L. This value approximates anticipated endogenous levels. Because the goal of the method is to detect GHB concentrations consistent with intoxication rather than lower endogenous concentrations, the lowest concentration selected for the determination of accuracy and precision was 5.0 rag/L, an order of magnitude above the absolute limit of quantitation. The limit of detection was 0.1 mg/L. For ruggedness, derivatives were stable at least for 24 h.
Saliva samples were directly derivatized without a previous extraction process. There were several reasons for this. First, because of the sample collection method, the final amount of saliva is not often significant. One microliter is easily available, but little more. Thus, to avoid analyte loss, no extraction was performed. Second, the ratio derivative solution/sample amount (1:100) is high enough to not show matrix interferences and to obtain a complete derivative reaction on GHB. Data obtained from validation were compared with results from sample prepared drying saliva before the derivative process. Surrogate recovery from saliva samples fell in the range of 94.6% to 100% with an average of 98.37% and a corresponding % RSD of 1.2%. These results confirm that no significant analyte loss was encountered.
A pool of 20 samples from laboratory personnel was analyzed. Values of GHB in the range of 2.0-3.0 mg/L were typical. One case showed a GHB concentration of 29.0 rag/L; the reason for this was unclear.
Conclusions
The primary goal of this work was to report a rapid, selective, and accurate toxicological screening method for the detection of GHB in saliva. Although the absolute limit of detection is on the order of anticipated endogenous levels, the method is intended and optimized for GHB concentrations expected as a result of intoxication. The method is highly sensitive and requires only 1.0 lJL of saliva for reliable quantification. Saliva can be collected non-invasively and by non-specialists. Derivatized samples are stable at least for 24 h. The use of a surrogate standard provides a quantitative measure of extraction and preparation efficiency that is matrix-specific. The method described could be applied to swab, neat saliva, and, as a future application, possibly physical evidence.
